Literature DB >> 15973212

[Colorectal carcinoma metastasis in livers infected with hepatitis B or C virus].

C Iascone1, M Ruperto, P Barillari.   

Abstract

AIM: Metastases from colorectal cancers rarely occur in injured livers, however in western countries this phenomenon has not been investigated in patients with various forms of chronic hepatitis. Therefore in this study we evaluated the incidence of synchronous hepatic metastases of colorectal carcinomas in patients with hepatitis B (HBV) or C (HBC) infection.
METHODS: Six hundred and thirty patients undergoing surgical treatment for colorectal carcinomas were analysed: the clinicopathological data of 87 patients with HBV or HCV infection (there were 29 patients with hepatitis C infection and 58 with hepatitis B infection) were compared to those of 543 non infected patients.
RESULTS: Patients distribution was similar in both groups in terms of gender, age, type of operative procedures performed, histological grading and lymph node metastases. Stage I, II or III tumours were similarly represented in non infected and infected patients, while stage IV tumours were 33.1% in the non infection group and 17.2% in the infection group (P < 0.001). At the time of surgery, synchronous extrahepatic metastases were present in 14.9% of non infected patients and 15% of infected patients, while synchronous hepatic metastases were found in 32% and 17.2% of patients respectively (P < 0.01).
CONCLUSIONS: Results of our study show that synchronous hepatic metastases of colorectal cancers are less frequently observed in chronic HBV or HCV infected patients than in non infected patients, while the incidence of extrahepatic metastases is comparable in both groups, suggesting that virus-related mechanisms and specific liver mediated immunity may have a protective role against neoplastic cell colonization of the liver.

Entities:  

Mesh:

Year:  2005        PMID: 15973212

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  6 in total

1.  Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis.

Authors:  Kevin M Waters; Tricia R Cottrell; Sepideh Besharati; Qingfeng Zhu; Robert A Anders
Journal:  Am J Clin Pathol       Date:  2019-01-07       Impact factor: 2.493

2.  Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis.

Authors:  Bin Cai; Kai Liao; Xian-qing Song; Wei-yuan Wei; Yuan Zhuang; Sen Zhang
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

Review 3.  The Effect of Diffuse Liver Diseases on the Occurrence of Liver Metastases in Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Filippo Monelli; Giulia Besutti; Olivera Djuric; Laura Bonvicini; Roberto Farì; Stefano Bonfatti; Guido Ligabue; Maria Chiara Bassi; Angela Damato; Candida Bonelli; Carmine Pinto; Pierpaolo Pattacini; Paolo Giorgi Rossi
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

4.  IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment.

Authors:  Mario Catarinella; Andrea Monestiroli; Giulia Escobar; Amleto Fiocchi; Ngoc Lan Tran; Roberto Aiolfi; Paolo Marra; Antonio Esposito; Federica Cipriani; Luca Aldrighetti; Matteo Iannacone; Luigi Naldini; Luca G Guidotti; Giovanni Sitia
Journal:  EMBO Mol Med       Date:  2016-02-01       Impact factor: 12.137

5.  Repression of let-7a cluster prevents adhesion of colorectal cancer cells by enforcing a mesenchymal phenotype in presence of liver inflammation.

Authors:  Lipeng Cheng; Li Geng; Binghua Dai; Tao Zheng; Jun Fu; Liang Qiao; Wenchang Cai; Yue Wang; Jiamei Yang
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

6.  Association between hepatitis B virus infection and colorectal liver metastasis: a meta-analysis.

Authors:  Rongqiang Liu; Weihao Kong; Mingbin Deng; Guozhen Lin; Tianxing Dai; Linsen Ye
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.